Drugs / EEA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05705414 | Oct 2024 → Jun 2026 overdue | end stage renal failure | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EEA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05705414 ↗ |
| Known as | EAA | “EAA will be administered as one 12.5 gm packet administered on dialysis treatment day followed by a washout and then Valine” NCT05705414 ↗ |
| Modality | Other / unclassified | “a combination of essential amino acids (EAA) supplementation” NCT05705414 ↗ |